- Report
- May 2023
- 270 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- October 2023
- 189 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 173 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- March 2023
- 113 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- April 2023
- 110 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- January 2024
- 141 Pages
Global
From €4056EUR$4,250USD£3,398GBP
- Report
- January 2024
- 145 Pages
Global
From €4056EUR$4,250USD£3,398GBP
- Report
- November 2023
- 118 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2024
- 100 Pages
Africa
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2024
- 300 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- January 2024
- 80 Pages
United States
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
United Kingdom
From €1432EUR$1,500USD£1,199GBP
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
South Korea
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
Saudi Arabia
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
India
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
Germany
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
France
From €1432EUR$1,500USD£1,199GBP
- Report
- January 2024
- 80 Pages
China
From €1432EUR$1,500USD£1,199GBP
- Report
- May 2022
- 40 Pages
Argentina
From €1432EUR$1,500USD£1,199GBP

Preimplantation Genetic Diagnosis (PGD) is a biotechnology procedure used to detect genetic abnormalities in embryos prior to implantation. It is used in conjunction with in vitro fertilization (IVF) to help couples with a family history of genetic disorders or those at risk of transmitting a genetic disorder to their offspring. PGD involves the removal of a single cell from an embryo and testing it for genetic abnormalities. The results of the test are then used to determine which embryos are suitable for implantation.
PGD has been used to detect a wide range of genetic disorders, including cystic fibrosis, Down syndrome, and Huntington's disease. It has also been used to detect chromosomal abnormalities, such as aneuploidy, which can lead to miscarriage or birth defects. PGD has been used to select embryos for gender selection, as well as to select embryos for tissue typing for bone marrow transplantation.
Companies in the Preimplantation Genetic Diagnosis market include Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Agilent Technologies, Inc., and Natera, Inc. Show Less Read more